Author:
Puissant Alexandre,Fenouille Nina,Alexe Gabriela,Pikman Yana,Bassil Christopher F.,Mehta Swapnil,Du Jinyan,Kazi Julhash U.,Luciano Frédéric,Rönnstrand Lars,Kung Andrew L.,Aster Jon C.,Galinsky Ilene,Stone Richard M.,DeAngelo Daniel J.,Hemann Michael T.,Stegmaier Kimberly
Subject
Cancer Research,Cell Biology,Oncology
Reference32 articles.
1. MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L;Bernt;Cancer Cell,2011
2. R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation;Braselmann;J. Pharmacol. Exp. Ther.,2006
3. Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor;Daigle;Cancer Cell,2011
4. Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics;DeAngelo;Blood,2006
5. Chromatin modifications as therapeutic targets in MLL-rearranged leukemia;Deshpande;Trends Immunol.,2012
Cited by
127 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献